Regeneron Wins Higher Bar At Trial For FCA Kickback Theory
A Massachusetts federal judge has ruled that the federal government must prove that alleged kickbacks by biotechnology company Regeneron related to its drug Eylea had a direct connection to false claims,...To view the full article, register now.
Already a subscriber? Click here to view full article